Semaglutide for Type 2 Diabetes (PORT Trial)

"As this trial is in Phase 1, the safety of Semaglutide Pen Injector [Ozempic] was rated as a score of 1 due to limited clinical evidence for efficacy and security."

"This clinical trial is open to individuals above the age of majority and below their 89th year."

"The Semaglutide Pen Injector [Ozempic] can be leveraged to tackle the challenges of long-term weight management, low caloric diets, and physical activity."

"Affirmative. According to the clinicaltrials.gov registry, this investigation is currently accepting participants and was first listed on April 11th 2022 with an update made July 29th of that same year. 600 individuals are sought from a solitary medical centre for inclusion in the study."

"Presently, 58 ongoing trials for Semaglutide Pen Injector [Ozempic] are located in 55 countries and 772 cities. Starting with its Phase 4 drug approval study from 2018 sponsored by Novo Nordisk A/S , there have been 123 separate clinical studies conducted involving 1387 patients."

"Currently, 58 trials are underway concerning Semaglutide Pen Injector [Ozempic], with 27 of them at the final stage. While primarily centered in Loma Linda, California, there is research being conducted across 3907 different locations worldwide."

"This clinical trial requires 600 Amish participants, aged between 18 and 89 years old, who are also overweight or obese (BMI ≥ 27 kg/m2)."

"The information posted on clinicaltrials.gov reveals that this medical experiment is currently recruiting participants. It was initially published on April 11th 2022 and the latest update was July 29th 2022."